Health care partner Tom Bulleit (Washington, D.C.) was quoted in a Law360 article that examines the impact of the coronavirus relief bill on drug pricing legislation. Tom explains that meaningful action on drug pricing in the short term is now more unlikely, because the legislative vehicle for that was intended to be the extension of certain Medicare provisions that were extended in the CARES Act (the Phase 3 COVID-19 response) through November 30. Because stand-alone legislation is harder to get passed, especially on a controversial topic, Tom speculates that the slim remaining prospect this year would be a lame duck session of Congress after the Nov. 3 U.S. elections.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.